EyeBio is a clinical-stage ophthalmology biotech company that brings together an experienced team of leaders, innovators, and entrepreneurs to develop a new generation of therapies for eye diseases. We understand what it takes to establish a new standard of care in ophthalmology. Our co-founders, Dr. David Guyer and Dr. Anthony P. Adamis, created and led the company that introduced the first anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).